Literature DB >> 7578874

Titin antibodies in patients with late onset myasthenia gravis: clinical correlations.

G O Skeie1, A Mygland, J A Aarli, N E Gilhus.   

Abstract

We have tested sera from 21 thymectomized patients with onset of MG after 40 years of age and without thymoma for antibodies against titin, using ELISA with the titin peptide MGT-30. Titin is a myofibrillar protein unique to striated muscle and important for the elastic recoil of muscle cells. Titin antibodies were detected in 9 of the 21 sera. MG symptoms as assessed by a 6 point disability score (0-5) were significantly more severe in the titin antibody positive patients both at peak of illness; 3.7 vs. 3.1 (p < 0.02) and at latest follow up; 2.1 vs. 0.8 (p < 0.01). All titin antibody positive patients were on immunosuppressive drug treatment at least follow-up, whereas only 3 of 12 patients without titin antibodies used immunosuppressive drugs. The presence of circulating titin antibodies in late-onset non-thymoma MG patients indicates a more severe disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578874     DOI: 10.3109/08916939509001933

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  9 in total

1.  Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis.

Authors:  Y Nemoto; S Kuwabara; S Misawa; N Kawaguchi; T Hattori; M Takamori; A Vincent
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

Review 2.  Autoantigens in systemic autoimmunity: critical partner in pathogenesis.

Authors:  A Rosen; L Casciola-Rosen
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

3.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

4.  Morvan's fibrillary chorea: a paraneoplastic manifestation of thymoma.

Authors:  E K Lee; R A Maselli; W G Ellis; M A Agius
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-12       Impact factor: 10.154

5.  Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.

Authors:  Isabell Cordts; Nicolas Bodart; Kathi Hartmann; Katerina Karagiorgou; John S Tzartos; Lin Mei; Jens Reimann; Philip Van Damme; Michael H Rivner; Alain Vigneron; Joachim Weis; Jörg B Schulz; Socrates J Tzartos; Kristl G Claeys
Journal:  J Neurol       Date:  2017-05-17       Impact factor: 4.849

Review 6.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

7.  Racial differences in myasthenia gravis in Alabama.

Authors:  Shin J Oh; Marla B Morgan; Liang Lu; Yuki Hatanaka; Shoji Hemmi; Angela Young; Gwendolyn C Claussen
Journal:  Muscle Nerve       Date:  2009-03       Impact factor: 3.217

8.  Thymoma in myasthenia gravis: from diagnosis to treatment.

Authors:  Fredrik Romi
Journal:  Autoimmune Dis       Date:  2011-08-10

9.  Myasthenia Gravis Following Excision of a Large Thymoma.

Authors:  Gyanendra Swaroop Mittal; B Niranjan Naik; Deepak Sundriyal
Journal:  Indian J Surg Oncol       Date:  2021-05-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.